click on circles to display study description...
olaparib (n=178) vs. Standard of Care (SoC) (n=88)
randomized controlled trial
olaparib 300 mg twice a day
SOC
physician's choice single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan)
ovarian cancer (OC)
open label
olaparib (n=196) vs. Standard of Care (SoC) (n=99)
randomized controlled trial
olaparib 300 mg in two 150 mg tablets, twice daily
placebo
ovarian cancer (OC)
maintenance treatment in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received at least two lines of previous chemotherapy
double-blind
international
olaparib (n=136) vs. Standard of Care (SoC) (n=129)
randomized controlled trial
olaparib, at a dose of 400 mg twice daily
placebo
ovarian cancer (OC)
patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen
double-blind
phase 2
olaparib (n=537) vs. Standard of Care (SoC) (n=269)
randomized controlled trial
olaparib plus bevacizumab
placebo plus bevacizumab
ovarian cancer (OC)
double-blind
olaparib (n=260) vs. Standard of Care (SoC) (n=131)
randomized controlled trial
olaparib tablets (300 mg twice daily)
during 2yr maintenance treatment
placebo
ovarian cancer (OC)
maintenance therapy in patients with newly diagnosed advanced (International Federation of Gynecology and Obstetrics stage III or IV) high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, or both ( BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy
double-blind
powered by vis.js Network